Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OliPass PTP1B antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- OliPass
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intraperitoneal
01
Overview
OliPass PTP1B antisense oligonucleotide is a preclinical-stage therapeutic candidate being developed by OliPass for the treatment of Type II Diabetes. The drug utilizes OliPass's proprietary Peptide Nucleic Acid (PNA) technology, which functions as an antisense oligonucleotide to modulate gene expression. Its specific mechanism of action involves inducing exon skipping in the mRNA of Protein-tyrosine phosphatase 1B (PTP1B), a key negative regulator of the insulin and leptin signaling pathways. By reducing the expression of PTP1B, the therapy aims to enhance insulin sensitivity and improve glucose homeostasis in patients with metabolic disorders.
- Other names
- OliPass PTP1B PNAPTP1B-antisense oligonucleotide (PNA)
02
Targets
PTPN1 (Protein tyrosine phosphatase 1B)
Beyond the preview
Go deeper on OliPass PTP1B antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OliPass PTP1B antisense oligonucleotide.